Xeris Biopharma Holdings, Inc. (XERS) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended June 30, 2024. Xeris Biopharma is a growth-oriented biopharmaceutical company commercializing three products: Gvoke (glucagon for severe hypoglycemia), Recorlev (cortisol synthesis inhibitor for Cushing's syndrome), and Keveyis (treatment for Primary Periodic Paralysis). The company also maintains a pipeline, including XP-8121 (once-weekly subcutaneous levothyroxine).
Key Financial Metrics
| Metric (in thousands) | Q2 2024 | Q2 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Total Revenue | $48,065 | $38,008 | $88,703 | $71,204 |
| Net Loss | $(15,005) | $(19,842) | $(33,985) | $(36,676) |
| Loss Per Share (Basic/Diluted) | $(0.10) | $(0.14) | $(0.24) | $(0.27) |
| Cash and Cash Equivalents | $57,604 | $46,170 | $57,604 | $46,170 |
| Short-term Investments | $19,964 | $5,002 | $19,964 | $5,002 |
| Long-term Debt (Net) | $230,481 | $190,932 | $230,481 | $190,932 |
| Accumulated Deficit | $(651,010) | $(591,446) | $(651,010) | $(591,446) |
Operating Cash Flow (YTD): Net cash used in operating activities was $30.7 million for the six months ended June 30, 2024, compared to $39.9 million in the prior year period.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 26.5% in Q2 and 24.6% YTD compared to 2023.
- Recorlev: Drove significant growth with an 86.1% increase in Q2 revenue ($13.3M vs $7.2M) due to higher volume and pricing.
- Gvoke: Increased 28.2% in Q2 ($20.0M vs $15.6M) driven by prescription growth.
- Keveyis: Declined 6.8% in Q2 ($13.1M vs $14.1M) due to lower volume.
- Expense Management: Operating loss narrowed significantly in Q2 ($8.2M vs $16.0M in 2023) despite higher SG&A, primarily due to revenue growth outpacing expense increases. R&D expenses decreased 5.4% in Q2 but increased 24.3% YTD due to pipeline spending.
- Debt Refinancing: In March 2024, the company entered an Amended and Restated Credit Agreement, refinancing existing debt. This resulted in $2.7 million in debt refinancing costs recorded in the first half of 2024 and increased interest expense.
- CVR Settlement: The company settled a contingent value rights (CVR) liability related to the Keveyis milestone by issuing 7.5 million shares of common stock, reducing the CVR liability from $20.5 million to $0.4 million.
Outlook, Risks, and Management Commentary
- Liquidity: Management believes current cash resources ($57.6M cash + $20.0M short-term investments) are sufficient to sustain operations for at least the next 12 months. However, the company expects to continue incurring net losses.
- Debt Maturity Risk: The 2029 Loans (Amended and Restated Credit Agreement) have a maturity date that could accelerate to January 15, 2025, if the 2025 Convertible Notes are not redeemed or extended. The company has a $15.2M Tranche 2 loan available specifically to redeem the 2025 Convertible Notes.
- Regulatory Risks: The company received an FDA untitled letter in June 2023 regarding Recorlev promotional materials, which was resolved with a close-out letter in August 2023. Ongoing compliance with FDA regulations remains a critical risk.
- Pipeline: The company is advancing XP-8121 (levothyroxine) and expects an FDA End-of-Phase 2 interaction by year-end 2024.
Investor Verification Checklist
- Debt Covenants & Maturity: Verify the status of the 2025 Convertible Notes ($15.2M outstanding) and the conditions triggering the accelerated maturity of the 2029 Loans in January 2025.
- Recorlev Growth Sustainability: Assess whether the 86% Q2 revenue growth for Recorlev is sustainable given the small addressable market for Cushing's syndrome.
- Cash Burn Rate: Monitor the trend in operating cash burn ($30.7M YTD) against the current cash balance to confirm the 12-month runway.
- Customer Concentration: Note that four customers accounted for 97% of gross product revenue in Q2 2024, creating significant concentration risk.
- Stock-Based Compensation: Review the $8.0M stock-based compensation expense YTD and the $28.0M of unrecognized RSU expense, which will impact future earnings.